Literature DB >> 24751819

Interleukin-21: a double-edged sword with therapeutic potential.

Rosanne Spolski1, Warren J Leonard1.   

Abstract

Interleukin-21 is a cytokine with broad pleiotropic actions that affect the differentiation and function of lymphoid and myeloid cells. Since its discovery in 2000, a tremendous amount has been learned about its biological actions and the molecular mechanisms controlling IL-21-mediated cellular responses. IL-21 regulates both innate and adaptive immune responses, and it not only has key roles in antitumour and antiviral responses but also exerts major effects on inflammatory responses that promote the development of autoimmune diseases and inflammatory disorders. Numerous studies have shown that enhancing or inhibiting the action of IL-21 has therapeutic effects in animal models of a wide range of diseases, and various clinical trials are underway. The current challenge is to understand how to specifically modulate the actions of IL-21 in the context of each specific immune response or pathological situation. In this Review, we provide an overview of the basic biology of IL-21 and discuss how this information has been - and can be - exploited therapeutically.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24751819     DOI: 10.1038/nrd4296

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN: 1474-1776            Impact factor:   84.694


  191 in total

1.  Functional STAT3 deficiency compromises the generation of human T follicular helper cells.

Authors:  Cindy S Ma; Danielle T Avery; Anna Chan; Marcel Batten; Jacinta Bustamante; Stephanie Boisson-Dupuis; Peter D Arkwright; Alexandra Y Kreins; Diana Averbuch; Dan Engelhard; Klaus Magdorf; Sara S Kilic; Yoshiyuki Minegishi; Shigeaki Nonoyama; Martyn A French; Sharon Choo; Joanne M Smart; Jane Peake; Melanie Wong; Paul Gray; Matthew C Cook; David A Fulcher; Jean-Laurent Casanova; Elissa K Deenick; Stuart G Tangye
Journal:  Blood       Date:  2012-03-08       Impact factor: 22.113

Review 2.  T follicular helper (TFH) cells in normal and dysregulated immune responses.

Authors:  Cecile King; Stuart G Tangye; Charles R Mackay
Journal:  Annu Rev Immunol       Date:  2008       Impact factor: 28.527

3.  A functional role for interleukin-21 in promoting the synthesis of the T-cell chemoattractant, MIP-3alpha, by gut epithelial cells.

Authors:  Roberta Caruso; Daniele Fina; Ilaria Peluso; Carmine Stolfi; Massimo Claudio Fantini; Valentina Gioia; Flavio Caprioli; Giovanna Del Vecchio Blanco; Omero Alessandro Paoluzi; Thomas T Macdonald; Francesco Pallone; Giovanni Monteleone
Journal:  Gastroenterology       Date:  2006-10-01       Impact factor: 22.682

4.  Interleukin-21 is upregulated in hepatitis B-related acute-on-chronic liver failure and associated with severity of liver disease.

Authors:  X Hu; S Ma; X Huang; X Jiang; X Zhu; H Gao; M Xu; J Sun; W G H Abbott; J Hou
Journal:  J Viral Hepat       Date:  2011-06-01       Impact factor: 3.728

5.  Interleukin-21 administration to rhesus macaques chronically infected with simian immunodeficiency virus increases cytotoxic effector molecules in T cells and NK cells and enhances B cell function without increasing immune activation or viral replication.

Authors:  Suresh Pallikkuth; Kenneth Rogers; Francois Villinger; Melvin Dosterii; Monica Vaccari; Genoveffa Franchini; Rajendra Pahwa; Savita Pahwa
Journal:  Vaccine       Date:  2011-10-11       Impact factor: 3.641

6.  Cutting edge: IL-21 is a switch factor for the production of IgG1 and IgG3 by human B cells.

Authors:  Jérôme Pène; Jean-François Gauchat; Sandrine Lécart; Elodie Drouet; Paul Guglielmi; Vera Boulay; Adriana Delwail; Don Foster; Jean-Claude Lecron; Hans Yssel
Journal:  J Immunol       Date:  2004-05-01       Impact factor: 5.422

7.  Interleukin-21 has activity in patients with metastatic melanoma: a phase II study.

Authors:  Teresa M Petrella; Richard Tozer; Karl Belanger; Kerry J Savage; Ralph Wong; Michael Smylie; Suzanne Kamel-Reid; Victor Tron; Bingshu E Chen; Naomi N Hunder; Linda Hagerman; Wendy Walsh; Elizabeth A Eisenhauer
Journal:  J Clin Oncol       Date:  2012-08-20       Impact factor: 44.544

8.  Anti-IL21 receptor monoclonal antibody (ATR-107): Safety, pharmacokinetics, and pharmacodynamic evaluation in healthy volunteers: a phase I, first-in-human study.

Authors:  Fei Hua; Gail M Comer; Lori Stockert; Bo Jin; John Nowak; Susan Pleasic-Williams; David Wunderlich; John Cheng; Jean S Beebe
Journal:  J Clin Pharmacol       Date:  2013-09-17       Impact factor: 3.126

9.  IL-21 regulates Th17 cells in rheumatoid arthritis.

Authors:  Xiaoyin Niu; Dongyi He; Xin Zhang; Tao Yue; Ningli Li; Jingwu Z Zhang; Chen Dong; Guangjie Chen
Journal:  Hum Immunol       Date:  2010-01-28       Impact factor: 2.850

10.  Differential regulation of B-cell proliferation by IL21 in different subsets of chronic lymphocytic leukemia.

Authors:  Ghasem Ghalamfarsa; Farhad Jadidi-Niaragh; Mohammad Hojjat-Farsangi; Hossein Asgarian-Omran; Mehdi Yousefi; Fathollah Tahmasebi; Jalal Khoshnoodi; Seyed Mohsen Razavi; Ali Akbar Saboor-Yaraghi; Hodjatallah Rabbani; Mahmood Jeddi-Tehrani; Fazel Shokri
Journal:  Cytokine       Date:  2013-04-09       Impact factor: 3.861

View more
  186 in total

1.  Activation of the FcgammaReceptorIIIa on human natural killer cells leads to increased expression of functional interleukin-21 receptor.

Authors:  Elizabeth L McMichael; Nicholas B Courtney; Megan C Duggan; Robert Wesolowski; Dionisia Quiroga; Sri Vidya Kondadasula; Lakhvir S Atwal; Neela Bhave; Eric Luedke; Alena Cristina Jaime-Ramirez; Amanda R Campbell; Xiaokui Mo; John C Byrd; William E Carson Iii
Journal:  Oncoimmunology       Date:  2017-05-02       Impact factor: 8.110

2.  Loss of interleukin-21 receptor activation in hypoxic endothelial cells impairs perfusion recovery after hindlimb ischemia.

Authors:  Tao Wang; Alexis Cunningham; Ayotunde O Dokun; Surovi Hazarika; Kevin Houston; Lingdan Chen; R John Lye; Rosanne Spolski; Warren J Leonard; Brian H Annex
Journal:  Arterioscler Thromb Vasc Biol       Date:  2015-04-02       Impact factor: 8.311

3.  Concurrent gut transcriptome and microbiota profiling following chronic ethanol consumption in nonhuman primates.

Authors:  Tasha Barr; Suhas Sureshchandra; Paul Ruegger; Jingfei Zhang; Wenxiu Ma; James Borneman; Kathleen Grant; Ilhem Messaoudi
Journal:  Gut Microbes       Date:  2018-04-27

4.  JAK-STAT-mediated chronic inflammation impairs cytotoxic T lymphocyte activation to decrease anti-PD-1 immunotherapy efficacy in pancreatic cancer.

Authors:  Chunwan Lu; Asif Talukder; Natasha M Savage; Nagendra Singh; Kebin Liu
Journal:  Oncoimmunology       Date:  2017-02-10       Impact factor: 8.110

5.  Toll-like receptor 3 in nasal CD103+ dendritic cells is involved in immunoglobulin A production.

Authors:  H Takaki; S Kure; H Oshiumi; Y Sakoda; T Suzuki; A Ainai; H Hasegawa; M Matsumoto; T Seya
Journal:  Mucosal Immunol       Date:  2017-06-15       Impact factor: 7.313

Review 6.  Citrobacter rodentium: a model enteropathogen for understanding the interplay of innate and adaptive components of type 3 immunity.

Authors:  D J Silberger; C L Zindl; C T Weaver
Journal:  Mucosal Immunol       Date:  2017-06-14       Impact factor: 7.313

Review 7.  Cytokines in the Treatment of Cancer.

Authors:  Kevin C Conlon; Milos D Miljkovic; Thomas A Waldmann
Journal:  J Interferon Cytokine Res       Date:  2018-06-11       Impact factor: 2.607

8.  Role of IL-21 in host pathogenesis in experimental visceral leishmaniasis.

Authors:  R Khatonier; A M Khan; P Sarmah; G U Ahmed
Journal:  J Parasit Dis       Date:  2018-08-22

9.  Interleukin-21 Regulates Natural Killer Cell Responses During Mycobacterium tuberculosis Infection.

Authors:  Padmaja Paidipally; Deepak Tripathi; Abhinav Van; Rajesh Kumar Radhakrishnan; Rohan Dhiman; Sambasivan Venkatasubramanian; Kamakshi P Devalraju; Amy R Tvinnereim; Vijaya Lakshmi Valluri; Ramakrishna Vankayalapati
Journal:  J Infect Dis       Date:  2018-03-28       Impact factor: 5.226

10.  Immune and Inflammatory Determinants Underlying Alzheimer's Disease Pathology.

Authors:  Janet E Baulch; Munjal M Acharya; Sudhanshu Agrawal; Lauren A Apodaca; Clarice Monteiro; Anshu Agrawal
Journal:  J Neuroimmune Pharmacol       Date:  2020-02-24       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.